Email updates

Keep up to date with the latest news and content from Clinical and Molecular Allergy and BioMed Central.

Open Access Highly Accessed Open Badges Research

Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA

Viswanath P Kurup1*, Alan P Knutsen2, Richard B Moss3 and Naveen K Bansal4

Author Affiliations

1 Allergy-Immunology Division, Medical College of Wisconsin and Research Service, V A Medical Center, 5000 West National Avenue, Milwaukee, WI 53295, USA

2 Pediatrics Research Institute, St. Louis University, Health Sciences, 3662 Park Avenue, St. Louis, MO 63110, USA

3 Division of Pediatric Pulmonology, Stanford University Medical School, 701A Welch Road, Suite 3328, Palo Alto, CA 94304, USA

4 Marquette University, P.O. Box 1881, Milwaukee, WI 53201, USA

For all author emails, please log on.

Clinical and Molecular Allergy 2006, 4:11  doi:10.1186/1476-7961-4-11

Published: 21 July 2006



Aspergillus fumigatus, a widely distributed fungus, has been implicated in causing life threatening infections as well as severe asthma and allergic diseases in man. Allergic affliction like allergic bronchopulmonary aspergillosis (ABPA) is a disabling lung disease frequently seen in patients with asthma and cystic fibrosis. Immunodiagnosis of the former is comparatively easier due to the availability of purified antigens and sensitive methods. However, this is not true with cystic fibrosis patients where the prevalence of ABPA is fairly high and the morbidity and mortality are significant.


In the present study, we have evaluated purified recombinant allergens from A. fumigatus, namely Asp f 1, f 2, f 3, f 4, and f 6 using ELISA and a semi-automated method (ImmunoCAP). We studied 17 patients each from cystic fibrosis with ABPA, and cystic fibrosis with asthma, 22 cystic fibrosis with no ABPA or asthma, and 11 age matched controls.


The results indicate that no antigen, antibody or method is capable of differentiating cystic fibrosis (CF) with ABPA from other CF patients, although some allergens showed strong reaction or showed more prevalence among the patients studied.


When results of several allergens such as Asp f 1, f 2, f 3, f 4, and f 6 in their binding to IgA, IgG, and IgE antibodies were analyzed, a more strong discrimination of CF patients with ABPA was possible from the other groups studied.